{"entity":{"id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial testing YL201 in small-cell lung cancer and non-small-cell lung cancer, now recruiting.","summary":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07739758, led by MediLink Therapeutics (Suzhou) with Shanghai Henlius Biotech, and recruiting on the registry. Official title: A Phase III, Multicenter, Randomised, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer. Planned enrolment is 442 participants (estimated). The study started in 2026-08-18 and primary completion is expected in 2029-06. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07739758","url":"https://clinicaltrials.gov/study/NCT07739758"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc","nsclc","extensive-stage-sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["yl201"],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07739758","phase":"3","setting":"A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","sponsor":"MediLink Therapeutics (Suzhou)","participation":[{"nct":"NCT07739758","source":"https://clinicaltrials.gov/study/NCT07739758","fetchedAt":"2026-10-07T16:56:10.647Z","studySha256":"64fa70bfb5ae84911b84e6e5bc7103c45270980864dbb68e77b75d5747cb6093","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-24","leadSponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":442,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["China"]}],"started":"2026-08-18","startedType":"actual","enrolled":442,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07739758/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}]}}